Vimarsana
Biggest News Aggregation in the World

Page 28 - Forward Looking Statement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Forward Looking Statement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Forward Looking Statement Today - Breaking & Trending Today

Vicor Corporation (NASDAQ:VICR) Q3 2023 Earnings Call Transcript - Vimarsana News

Vicor Corporation (NASDAQ:VICR) Q3 2023 Earnings Call Transcript

Vicor Corporation (NASDAQ:VICR) Q3 2023 Earnings Call Transcript October 24, 2023 Vicor Corporation beats earnings expectations. Reported EPS is $0.37, expectations were $0.31. Operator: Welcome, everyone to today’s webinar entitled Vicor Earnings Results for the Third Quarter Ended September 30, 2023. My name is Jono [ph] and I’m your producer for today. [Operator Instructions] I […]

Source: yahoo.com
Helix Energy Solutions Group, Inc. (NYSE:HLX) Q3 2023 Earnings Call Transcript - Vimarsana News

Helix Energy Solutions Group, Inc. (NYSE:HLX) Q3 2023 Earnings Call Transcript

Helix Energy Solutions Group, Inc. (NYSE:HLX) Q3 2023 Earnings Call Transcript October 24, 2023 Operator: Greetings and welcome to the Third Quarter Helix Energy Solutions 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded on Tuesday, October 24, 2023. I would now like to turn the conference over to Mr. […]

Source: yahoo.com
ICON Public : Q3 2023 Results_FINAL -October 25, 2023 at 04:42 pm EDT - Vimarsana News

ICON Public : Q3 2023 Results_FINAL -October 25, 2023 at 04:42 pm EDT

ICON Q3 2023 Results Period Ended September 30, 2023 Dr. Steve Cutler, CEO Brendan Brennan, CFO ...

Silver Lake has Purchased the Remaining 5% Shareholding from Software ... - Vimarsana News

Silver Lake has Purchased the Remaining 5% Shareholding from Software ...

Silver Lake has Purchased the Remaining 5% Shareholding from Software ...

The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA) - Vimarsana News

The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)

SYFOVRE demonstrated clinically meaningful reductions in GA lesion growth in as few as six doses per yearOnly treatment approved for use beyond 12...